X
Roivant wins $200m backing to expand R&D operations
https://pharmaphorum.com/news/roivant-wins-200m-backing-to-expand-rd-operations/
Roivant
Ramaswamy’s Roivant signs diabetes drug deal with Poxel
Biotech entrepreneur hopes to bounce back from Alzheimer’s disappointment
Axovant CEO David Hung quits after Alzheimer’s drug failure
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
